Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor

Journal of Nutritional Biochemistry

Volumn 19, Issue 12, 2008, Pages 848-855

  Hong, Mee Young ^a   Seeram, Navindra P ^a   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen independence; Androgen receptor; Ellagic acid; Pomegranate; Prostate cancer; Punicalagin

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ELLAGITANNIN; HYDROXYSTEROID DEHYDROGENASE; OXIDOREDUCTASE; POLYPHENOL DERIVATIVE; POMEGRANATE EXTRACT; POMEGRANATE POLYPHENOL; STEROID 5ALPHA REDUCTASE 1; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; POMEGRANATE; POMEGRANATE JUICE; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; DOWN-REGULATION; ESTRADIOL; FLAVONOIDS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PHENOLS; PLANT EXTRACTS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PUNICACEAE; RECEPTORS, ANDROGEN;

LYTHRACEAE;

EID: 53249094494     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2007.11.006     Document Type: Article

References (52)

1. Gil M.I., Tomas-Barberan F.A., Hess-Pierce B., Holcroft D.M., and Kader A.A. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 48 (2000) 4581-4589
2. Aviram M., Dornfield L., Rosenblatt M., Volkova N., Kaplan M., Coleman R., et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 71 (2000) 1062-1076
3. Kaplan M., Hayek T., Raz A., Coleman R., Dornfield L., Vaya J., et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 131 (2001) 2082-2089
4. Kim N.D., Mehta R., Yu W., Neeman I., Livney T., Amichay A., et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71 (2002) 203-217
5. Cerda B., Ceron J.J., Tomas-Barberan F.A., and Espin J.C. Repeated oral administration of high doses of pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem 51 (2003) 3493-3501
6. Cerda B., Llorach R., Ceron J.J., Espin J.C., and Tomas-Barberan F.A. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 42 (2003) 18-28
7. Narayanan B.A., Geoffrey O., Willingham M.C., Re G.G., and Nixon D.W. p53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 136 (1999) 215-221
8. Khanduja K.L., Gandhi R.K., Pathania V., and Syanl N. Prevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol 137 (1999) 313-318
9. Mertens-Talcott S.U., Talcott S.T., and Percival S.S. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J Nutr 133 (2003) 2669-2674
10. Adams L.S., Seeram N.P., Aggarwal B.B., Takada Y., Sand D., and Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 54 (2006) 980-985
11. Albrecht M., Jiang W., Kumi-Diaka J., Lansky E.P., Gommersall L.M., Mansel R.E., et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7 (2004) 274-283
12. Kawaii S., and Lansky E.P. Differentiation-promoting activity of pomegranate (Punica granatum) fruit extracts in HL-60 human promyelocytic leukemia cells. J Med Food 7 (2004) 13-18
13. Toi M., Bando H., Ramachandran C., Melnick S.J., Imai A., Fife R.S., et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 6 (2003) 121-128
14. Hora J.J., Maydew E.R., Lansky E.P., and Dwivedi C. Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J Med Food 6 (2003) 157-161
15. Kohno H., Suzuki R., Yasui Y., Hosokawa M., Miyashita K., and Tanaka T. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Sci 95 (2004) 481-486
16. American Cancer Society. Cancer facts and figures 2007 (2007). http://www.cancer.org Atlanta (Ga)
17. Pienta K.J., and Esper P.S. Risk factors for prostate cancer. Ann Intern Med 118 (1993) 793-803
18. Denis L.J., and Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 18 (2000) 52-74
19. Thompson I., Feigl P., and Coltman C. Chemoprevention of prostate cancer with finasteride. Important Adv Oncol (1995) 57-76
20. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr Rev 25 (2004) 276-308
21. Stanbrough M., Leav I., Kwan P.W., Bubley G.J., and Balk S.P. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A 98 (2001) 10823-10828
22. Attard G., Sarker D., Reid A., Molife R., Parker C., and de Bono J.S. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 95 (2006) 767-774
23. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
24. Kokontis J.M., Hay N., and Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12 (1998) 941-953
25. Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81 (1999) 242-251
26. Zhang L., Johnson M., Le K.H., Sato M., Ilagan R., Iyer M., et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 63 (2003) 4552-4560
27. Block G., Patterson B., and Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18 (1992) 1-29
28. Seeram N.P., Lee R., Hardy M.L., and Heber D. Large-scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. Sep Purif Tech 41 (2005) 49-55
29. Longtin R. The pomegranate: nature's power fruit?. J Natl Cancer Inst 95 (2003) 346-348
30. Pantuck A.J., Leppert J.T., Zomorodian N., Aronson W., Hong J., Barnard R.J., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12 (2006) 4018-4026
31. Seeram N.P., Aronson W., Zhang Y., Henning S.M., Moro A., Lee R., et al. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55 (2007) 7732-7737
32. Jariwala U., Prescott J., Jia L., Barski A., Pregizer S., Cogan J.P., et al. Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 6 (2007) 39
33. Kim D., Gregory C.W., French F.S., Smith G.J., and Mohler J.L. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 160 (2002) 219-226
34. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
35. Callewaert L., Van Tilborgh N., and Claessens F. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 66 (2006) 543-553
36. Devgan S.A., Henderson B.E., Yu M.C., Shi C.Y., Pike M.C., Ross R.K., et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 33 (1997) 9-12
37. Fung K.M., Samara E.N., Wong C., Metwalli A., Krlin R., Bane B., et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13 (2006) 169-180
38. Torres J.M., Ruiz E., and Ortega E. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status. Prostate 56 (2003) 74-79
39. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
40. Steers W.D. 5alpha-reductase activity in the prostate. Urology 58 (2001) 17-24
41. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
42. Agís-Balboa R.C., Pinna G., Zhubi A., Maloku E., Veldic M., Costa E., et al. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci U S A 103 (2006) 14602-14607
43. McCartin S., Russell A.J., Fisher R.A., Wallace A.M., Arnhold I.J., Mason J.I., et al. Phenotypic variability and origins of mutations in the gene encoding 3beta-hydroxysteroid dehydrogenase type II. J Mol Endocrinol 24 (2000) 75-82
44. Bird I.M., Pasquarette M.M., Rainey W.E., and Mason J.I. Differential control of 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. J Clin Endocrinol Metab 81 (1996) 2171-2178
45. Steckelbroeck S., Jin Y., Gopishetty S., Oyesanmi B., and Penning T.M. Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity. J Biol Chem 279 (2004) 10784-10795
46. Zhou Z., and Speiser P.W. Regulation of HSD17B1 and SRD5A1 in lymphocytes. Mol Genet Metab 68 (1999) 410-417
47. Arnold J.T., Le H., McFann K.K., and Blackman M.R. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 288 (2005) E573-E584
48. King K.J., Nicholson H.D., and Assinder S.J. Effect of increasing ratio of estrogen:androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. Prostate 66 (2006) 105-114
49. Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., and Gao A.C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9 (2003) 370-376
50. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138 (1997) 3290-3298
51. Malik A., and Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 5 (2006) 371-373
52. Seeram N.P., Adams L.S., Henning S.M., Niu Y., Zhang Y., Nair M.G., et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16 (2005) 360-367